Clinical Trials Logo

Major Depressive Disorder clinical trials

View clinical trials related to Major Depressive Disorder.

Filter by:

NCT ID: NCT03771664 Not yet recruiting - Clinical trials for Major Depressive Disorder

A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Subjects With Comorbid Major Depressive Disorder and Insomnia

Start date: December 2018
Phase: Phase 3
Study type: Interventional

This study is a randomized, double-blind, placebo-controlled study of the safety, tolerability, and efficacy of SAGE-217 compared to placebo in adult subjects with comorbid major depressive disorder and insomnia

NCT ID: NCT03769350 Not yet recruiting - Clinical trials for Major Depressive Disorder

Waitlist-Control Trial of Smartphone CBT for Major Depressive Disorder (MDD)

Start date: April 1, 2019
Phase: N/A
Study type: Interventional

The investigators are testing a Smartphone-delivered cognitive behavioral therapy (CBT) treatment for major depressive disorder (MDD).

NCT ID: NCT03766867 Recruiting - Clinical trials for Major Depressive Disorder

Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression

Start date: December 3, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of vortioxetine given as a single intravenous dose of 25 mg at initiation of an oral vortioxetine regimen of 10 mg/day for 7 days

NCT ID: NCT03761030 Not yet recruiting - Depression Clinical Trials

L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults

Start date: December 1, 2018
Phase: N/A
Study type: Interventional

Individuals with Late Life Depression (LLD) often have cognitive problems, particularly problems with memory, attention, and problem solving, all of which contribute to antidepressant non-response. Our group and others have shown that decreased thinking speed is the central cause of functional problems in patients with LLD. Similarly, decreased walking speed is associated with depression and carries additional risk for falls, hospitalization, and death. Available evidence suggests that declining functionality in the brain's dopamine system contributes to age-related cognitive and motor slowing. The central hypothesis of this study is that by enhancing dopamine functioning in the brain and improving cognitive and motor slowing, administration of carbidopa/levodopa (L-DOPA) will improve depressive symptoms in older adults.

NCT ID: NCT03749629 Not yet recruiting - Clinical trials for Major Depressive Disorder

Comparative Effectiveness of Pharmacogenomics for Treatment of Depression

CEPIO-D
Start date: February 1, 2019
Phase: N/A
Study type: Interventional

The overall goal of this study is to assess the effectiveness of a widely available and widely used combinatorial pharmacogenomic (PGx) test for the treatment of major depressive disorder. Pharmacogenomic tests use genetic information to guide medication treatment decisions. The tests inform clinicians and patients of potential gene-drug interactions by analyzing pharmacokinetic (PK) genes (how drugs are metabolized) as well as pharmacodynamic (PD) genes (how drugs work). While combinatorial PGx testing is attractive to clinicians, patients, healthcare systems, and insurers, limited data demonstrate that PGx testing will result in better outcomes compared to evidence-based guideline treatment. Therefore, the investigators will conduct a prospective randomized comparative effectiveness study of best practice guidelines plus combinatorial PGx-guided treatment versus best-practice guideline concordant treatment alone.

NCT ID: NCT03748446 Not yet recruiting - Clinical trials for Major Depressive Disorder

Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder

Start date: December 15, 2018
Phase: Early Phase 1
Study type: Interventional

The investigators will test the hypothesis that inhaled xenon will produce a rapid improvement in depressive symptoms in patients suffering from treatment-resistant depression. Specifically, the investigators will conduct a parallel randomized, double-blind crossover study that will compare the effects of xenon-oxygen (35:65 ratio by volume) added to treatment as usual (X-TAU group) to the effects of nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual (N-TAU group). A total of 20 severely depressed patients, 10 with major depressive disorder (MDD) and 10 with Bipolar Depression (BP), will be exposed in random order to N-TAU and X-TAU in a double-blind protocol.

NCT ID: NCT03742960 Not yet recruiting - Clinical trials for Major Depressive Disorder

Sleep Subtypes in Adolescent Depression

Start date: December 1, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to compare sleep neurophysiology and behavior in adolescents with MDD with hypersomnia (MDD-HYP) and insomnia (MDD-INS) with healthy controls (HC). In addition, the investigators will test the efficacy of a simple behavioral sleep restriction on mood and sleep in their sample.

NCT ID: NCT03739632 Not yet recruiting - Clinical trials for Major Depressive Disorder

to Explore the Effective Doses, and to Assess the Safety and Efficacy of Hypidone Hydrochloride Tablets

Start date: November 15, 2018
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the safety and efficacy of Hypidone Hydrochloride tablets in treatment of patients with major depressive disorder (MDD) by evaluating the change of MADRS total scores from baseline to week 6.

NCT ID: NCT03739203 Recruiting - Clinical trials for Major Depressive Disorder

The Object of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

Start date: November 10, 2018
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD who have had an inadequate response to antidepressants alone

NCT ID: NCT03738215 Not yet recruiting - Clinical trials for Major Depressive Disorder

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

Start date: November 12, 2018
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD who have had an inadequate response to antidepressants alone